Property:Outcome specification
This is a property of type Text.
K
Kirste et al. (2011): Boswellia serrata Acts on Cerebral Edema in Patients Irradiated for Brain Tumors. A Prospective, Randomized, Placebo-Controlled, Double-Blind Pilot Trial +
NA +
Kirste et al. (2011): Boswellia serrata Acts on Cerebral Edema in Patients Irradiated for Brain Tumors. A Prospective, Randomized, Placebo-Controlled, Double-Blind Pilot Trial +
T2-weighted magnetic resonance imaging (MRI) after therapy compared with volume at baseline +
Kirste et al. (2011): Boswellia serrata Acts on Cerebral Edema in Patients Irradiated for Brain Tumors. A Prospective, Randomized, Placebo-Controlled, Double-Blind Pilot Trial +
Dexamethasone +
Kirste et al. (2011): Boswellia serrata Acts on Cerebral Edema in Patients Irradiated for Brain Tumors. A Prospective, Randomized, Placebo-Controlled, Double-Blind Pilot Trial +
T2-weighted magnetic resonance imaging (MRI) after therapy compared with volume at baseline +
Kirste et al. (2011): Boswellia serrata Acts on Cerebral Edema in Patients Irradiated for Brain Tumors. A Prospective, Randomized, Placebo-Controlled, Double-Blind Pilot Trial +
T2-weighted magnetic resonance imaging (MRI) after therapy compared with volume at baseline +
Kirste et al. (2011): Boswellia serrata Acts on Cerebral Edema in Patients Irradiated for Brain Tumors. A Prospective, Randomized, Placebo-Controlled, Double-Blind Pilot Trial +
Mental Functioning +
Konmun et al. (2017): A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy +
Health-related quality of life (day 1, 22, 23, and 64 of treatment) +
Konmun et al. (2017): A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy +
Response rate (i.e. no emetic events, no emergency medication) for first cycle of chemotherapy (day 1-5 of chemotherapy) for overall, acute (up to 24h after chemotherapy), and delayed (24-120h after chemotherapy) phase +
Konmun et al. (2017): A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy +
Change of appetite score +
Konmun et al. (2017): A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy +
Nausea and vomiting (severity, day 1-5 of chemotherapy) +
Konmun et al. (2017): A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy +
Response rate (i.e. no emetic events, no emergency medication) over all 3 cycles for overall, acute (up to 24h after chemotherapy), and delayed (24-120h after chemotherapy) phase +
Konmun et al. (2017): A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy +
Side effects (continuous until 30 days after last intervention) +
Kottschade et al. (2011): The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase 3 clinical trial +
Start of sensory neuropathy +
Kottschade et al. (2011): The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase 3 clinical trial +
Sensory Neuropathie +
Kottschade et al. (2011): The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase 3 clinical trial +
Length of sensory neuropathy (Onset of symptoms to reduction of symptoms ≥ grade 1) +
Koyama et al. (2017): Intravenous Carnitine Administration in Addition to Parenteral Nutrition With Lipid Emulsion May Decrease the Inflammatory Reaction in Postoperative Surgical Patients +
Reduction of complication rates: infectious, mechanical, overall after surgery +
Kraft et al. (2012): L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN) - a randomized multicentre trial +
From diagnosis to death +
Kraft et al. (2012): L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN) - a randomized multicentre trial +
BMI and body composition (BIA) : baseline + 6, 12 weeks +